Nebivolol is more effective than atenolol for blood pressure variability attenuation and target organ damage prevention in L-NAME hypertensive rats

β-Adrenergic blockers are no longer recommended as first-line therapy due to the reduced cardioprotection of traditional β-blockers compared with other antihypertensive drugs. It is unknown whether third-generation β-blockers share the limitations of traditional β-blockers. The aim of the present st...

Full description

Saved in:
Bibliographic Details
Published in:Hypertension research 2021-07, Vol.44 (7), p.791-802
Main Authors: Del Mauro, Julieta S, Prince, Paula D, Santander Plantamura, Yanina, Allo, Miguel A, Parola, Luciano, Fernandez Machulsky, Nahuel, Morettón, Marcela A, Bin, Eliana P, González, Germán E, Bertera, Facundo M, Carranza, Andrea, Berg, Gabriela, Taira, Carlos A, Donato, Martín, Chiappetta, Diego A, Polizio, Ariel H, Höcht, Christian
Format: Article
Language:English
Subjects:
Animals
Antihypertensive Agents - pharmacology
Atenolol - pharmacology
Blood pressure
Blood Pressure - drug effects
Blood Pressure - physiology
Coronary vessels
Disease prevention
Hypertension
Hypertension - drug therapy
Male
Nebivolol - pharmacology
Rats
Rats, Wistar
Rodents
Treatment Outcome
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:β-Adrenergic blockers are no longer recommended as first-line therapy due to the reduced cardioprotection of traditional β-blockers compared with other antihypertensive drugs. It is unknown whether third-generation β-blockers share the limitations of traditional β-blockers. The aim of the present study was to compare the effects of nebivolol or atenolol on central and peripheral systolic blood pressure (SBP) and its variability and target organ damage (TOD) in N-nitro-L-arginine methyl ester (L-NAME) hypertensive rats. Male Wistar rats were treated with L-NAME for 8 weeks together with oral administration of nebivolol 30 mg/kg (n = 8), atenolol 90 mg/kg (n = 8), or vehicle (n = 8). The control group was composed of vehicle-treated Wistar rats. SBP and its variability, as well as echocardiographic parameters, were assessed during the last 2 weeks of treatment. Tissue levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and transforming growth factor β (TGF-β), and histopathological parameters were evaluated in the left ventricle and aorta. Nebivolol had a greater ability than atenolol to decrease central SBP and mid-term and short-term blood pressure variability (BPV) in L-NAME rats. Echocardiographic analysis showed that nebivolol was more effective than atenolol on E/A wave ratio normalization. Compared with atenolol treatment, nebivolol had a greater protective effect on different TOD markers, inducing a decrease in collagen deposition and a reduction in the proinflammatory cytokines IL-6 and TNF-α in the left ventricle and aorta. Our findings suggest that the adverse hemodynamic profile and the reduced cardiovascular protection reported with traditional β-blockers must not be carried forward to third-generation β-blockers.
ISSN:0916-9636
1348-4214
DOI:10.1038/s41440-021-00630-4